Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.30 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.30 |
| ▸ | ITGAL | P20701 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1221420 | 1.00 | ECE1 (0.38) | ECE1MEN1USP2ALDH1A1MAPT | |
| SCHEMBL8364638 | 0.88 | ECE1 (0.34) | ECE1 | |
| SCHEMBL1374076 | 0.88 | ECE1 (0.36) | ECE1 | |
| SCHEMBL1374080 | 0.88 | ECE1 (0.36) | ECE1 | |
| SCHEMBL1226547 | 0.85 | ECE1 (0.41) | ECE1MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL1226550 | 0.85 | ECE1 (0.41) | ECE1MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL5144359 | 0.85 | GABRR1 (0.32) | MEN1USP2ALDH1A1MAPTKMT2A | |
| SCHEMBL4030392 | 0.85 | GABRR1 (0.32) | MEN1USP2ALDH1A1MAPTKMT2A | |
| SCHEMBL4553554 | 0.85 | GABRR1 (0.32) | MEN1USP2ALDH1A1MAPTKMT2A | |
| SCHEMBL3229885 | 0.84 | TDP1 (0.36) | ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4545964-A2 | CHROMATOGRAPHIC ISOLATION OF CELLS AND OTHER COMPLEX BIOLOGICAL MATERIALS | Juno Therapeutics GmbH (DE) | 2025-04-30 | — | — | EP | claimed |
| WO-2025083196-A1 | A METHOD OF MANUFACTURING A CELLULAR THERAPY PRODUCT AND RESPECTIVE KITS AND DEVICES | TQ THERAPEUTICS GMBH (DE) | 2025-04-24 | — | — | WO | claimed |
| US-20250020556-A1 | CHROMATOGRAPHIC ISOLATION OF CELLS AND OTHER COMPLEX BIOLOGICAL MATERIALS | JUNO THERAPEUTICS GMBH (DE) | 2025-01-16 | — | — | US | claimed |
| EP-2817625-B1 | CHROMATOGRAPHIC ISOLATION OF CELLS AND OTHER COMPLEX BIOLOGICAL MATERIALS | JUNO THERAPEUTICS GMBH (DE) | 2025-01-01 | — | — | EP | claimed |
| US-20230173080-A1 | COMPOSITION OF IMMUNOMODULATING SERPIN, SERP-1 | SERPASS BIOLOGICS, INC. | 2023-06-08 | — | — | US | claimed |
| EP-4143222-A2 | COMPOSITION OF IMMUNOMODULATING SERPIN, SERP-1 | Arizona Board of Regents on behalf of Arizona State University (US) | 2023-03-08 | — | — | EP | claimed |
| US-20220275041-A1 | MODIFIED IFNL3 POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCING MOIETY AND THEIR USES | EXALT THERAPEUTICS, LLC | 2022-09-01 | — | — | US | claimed |
| US-20220056083-A1 | STREPTAVIDIN MUTEINS AND METHODS OF USING THEM | IBA LIFESCIENCES GMBH (GI) | 2022-02-24 | — | — | US | claimed |
| CN-103083681-A | Drug for treating tumors and application thereof | UNIV TSINGHUA | 2013-05-08 | — | — | CN | claimed |
| CN-101596320-A | A kind of medicine and application thereof for the treatment of tumor | UNIV TSINGHUA (CN) | 2009-12-09 | — | — | CN | claimed |
| CN-101405019-A | Medicine for treating tumor and application thereof | UNIV TSINGHUA (CN) | 2009-04-08 | — | — | CN | claimed |
| CN-101002946-A | Medicine for treating tumor and application thereof | UNIV TSINGHUA (CN) | 2007-07-25 | — | — | CN | claimed |
| EP-0788375-A3 | — | OFFORD ROBIN EWART | 1997-09-17 | — | — | EP | claimed |
| EP-0788375-A2 | FUNCTIONALIZED POLYMERS FOR SITE-SPECIFIC ATTACHMENT | Offord, Robin Ewart (CH) | 1997-08-13 | — | — | EP | claimed |
| WO-1996041813-A9 | FUNCTIONALIZED POLYMERS FOR SITE-SPECIFIC ATTACHMENT | — | 1997-06-19 | — | — | WO | claimed |
| WO-1996041813-A2 | FUNCTIONALIZED POLYMERS FOR SITE-SPECIFIC ATTACHMENT | OFFORD ROBIN E (CH) | 1996-12-27 | — | — | WO | claimed |
| US-12622944-B2 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | AMBRX, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4104853-B1 | ARGININE DEIMINASE WITH REDUCED CROSS-REACTIVITY TOWARD ADI - PEG 20 ANTIBODIES FOR CANCER TREATMENT | POLARIS GROUP (KY) | 2026-05-06 | — | — | EP | disclosed |
| EP-0685504-A2 | Polyaspartic acid derivatives and process for preparing the same | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1995-12-06 | — | — | EP | disclosed |
| EP-0539167-A2 | Peg imidates and protein derivatives thereof | ORTHO PHARMACEUTICAL CORPORATION (US) | 1993-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220275041-A1 | MODIFIED IFNL3 POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCING MOIETY AND THEIR USES | IFNG, IRF3, IFNAR1 | ECE1 2267/4885MEN1 2902/4885USP2 2058/4885 |
| US-12622944-B2 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | DDOST, DMPK, KRTCAP2 | ECE1 2096/4885MEN1 4217/4885USP2 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.